Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

A group of Entrada Therapeutics , Inc. (NASDAQ:TRDA) ten percent owners, including 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., reported selling shares of common stock worth approximately $866632. The sales occurred between June 27 and July 1, 2025, with prices ranging from $6.8127 to $7.1226 per share. The transactions come as the stock trades near $7.09, down nearly 60% over the past six months. According to InvestingPro data, analysts maintain a bullish stance with price targets between $20-21, suggesting significant upside potential.

5AM Ventures V, L.P. directly disposed of 55,735 shares on June 27 at $6.91 per share, and another 18,578 shares on June 30 at $6.8127 per share, followed by 18,578 shares on July 1 at $7.1226 per share. Following these transactions, 5AM Ventures V, L.P. directly holds 3,183,131 shares.

Additionally, 5AM Opportunities I, L.P. indirectly sold 19,265 shares on June 27 at $6.91 per share, 6,422 shares on June 30 at $6.8127 per share, and 6,422 shares on July 1 at $7.1226 per share. After these transactions, 5AM Opportunities I, L.P. indirectly holds 1,100,248 shares.

5AM Partners V, LLC is the sole general partner of 5AM Ventures V, L.P., while 5AM Opportunities I (GP), LLC is the sole general partner of 5AM Opportunities I, L.P. Andrew J. Schwab and Scott M. Rocklage are managing members of 5AM Partners V, LLC, and Andrew J. Schwab and Kush Parmar are managing members of 5AM Opportunities I (GP), LLC. Each of 5AM Partners, Opportunities GP, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares except to the extent of their pecuniary interest. Notably, the stock has historically shown a negative correlation with the broader market, with a beta of -0.06, making it a potential portfolio diversification tool.

In other recent news, Entrada Therapeutics has received regulatory approvals to initiate a new clinical study in Europe and the United Kingdom (TADAWUL:4280). The study, named ELEVATE-45-201, is a Phase 1/2 trial designed to evaluate the safety, tolerability, and effectiveness of ENTR-601-45 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. This trial is set to begin in the third quarter of 2025 and will involve approximately 24 ambulatory DMD patients. The trial will be conducted in two parts, focusing first on safety and optimal dosing, then assessing the drug’s efficacy. H.C. Wainwright analysts reaffirmed a Buy rating on Entrada Therapeutics, maintaining a $20.00 price target, following these regulatory approvals. The study represents a significant step in Entrada’s broader DMD franchise, which includes other exon-skipping candidates. Entrada plans to submit global regulatory applications for additional candidates, ENTR-601-50 and ENTR-601-51, in the coming years. These developments are part of the company’s strategic plan to advance its pipeline of therapeutics targeting neuromuscular and ocular diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.